A series of hybrid molecules of 1,1-diarylethylenes (isoCA-4) and belinostat (77) (Figure 25), an HDAC inhibitor and a drug approved in hematological malignancies and solid tumors, was designed and synthesized. This evidence concerns the gene HDAC9 and hematologic disorder.